JUN 15·SEC EDGARLow
Davis Todd C purchased $1,000K of PTHS
Davis Todd C purchased 35,948 shares of Pelthos Therapeutics Inc. (PTHS) at an average of $27.82 ($27.80–$28.73, $1.00M total) across 2 trades on 2026-06-11.
StockNYSE · US · USDHealthcare · BIOTECHNOLOGY
$PTHS
Pelthos Therapeutics Inc.
Price · $PTHSvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $PTHS in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $PTHS in the last 30 days.
See all $PTHS insider activity →Top stories · $PTHSMore →
MAY 28·manilatimes.net
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. (NYSE American: PTHS) said CEO Scott Plesha will present at 11:05 a.m. ET and take part in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The company noted investors can arrange meetings via their Jefferies representative.
MAY 26·SEC EDGAR
Francis Knuettel II sold (to issuer) 13,947 shares of PTHS
Francis Knuettel II (CFO, Treas & Secty) sold (to issuer) 13,947 shares of Pelthos Therapeutics Inc. (PTHS) on 2026-05-22.
PTHS sentiment & insider activity
Recent PTHS coverage spans financial news and insider activity.
What's driving PTHS
Insider buying can be a modest sentiment tailwind, but it is not a fundamental catalyst by itself.
Conference participation is typically a low-volatility catalyst unless accompanied by new clinical/commercial datapoints or guidance.
This is an insider Form 4 sale to the issuer; without disclosed price/value, it’s more of a sentiment/flow signal than a fundamental catalyst.
Pelthos Therapeutics' participation in investor conferences may positively influence its stock due to increased visibility and investor interest.
The FDA approval and positive trial results for Zelsuvmi suggest potential positive impact on Pelthos Therapeutics' stock price in the near term.
alphai scores every news story that mentions PTHS with an AI model for sentiment and relevance, and aggregates insider trades from Pelthos Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PTHS
Score
Davis Todd C purchased $1,000K of PTHS
Davis Todd C purchased 35,948 shares of Pelthos Therapeutics Inc. (PTHS) at an average of $27.82 ($27.80–$28.73, $1.00M total) across 2 trades on 2026-06-11.
1 min read
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. (NYSE American: PTHS) said CEO Scott Plesha will present at 11:05 a.m. ET and take part in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The company noted investors can arrange meetings via their Jefferies representative.
2 min readFrancis Knuettel II sold (to issuer) 13,947 shares of PTHS
Francis Knuettel II (CFO, Treas & Secty) sold (to issuer) 13,947 shares of Pelthos Therapeutics Inc. (PTHS) on 2026-05-22.
1 min read
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences - Pelthos Therapeutics (AMEX:PTHS)
DURHAM, N.C., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. PTHS, a biopharmaceutical company ( "Pelthos" or the "Company" ) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, ...
3 min read
Why Is Pelthos Therapeutics Stock Trading Higher Thursday - Pelthos Therapeutics (AMEX:PTHS)
Zelsuvmi cleared all molluscum lesions in 33% of patients vs. 19.7% on placebo by week 12 in 891-patient trial. Zelsuvmi is FDA-approved for at-home use in adults and children as young as one year old. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the ...
4 min read